The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

Publications

Bilal J, Riaz IB, Hill JL, Zangeneh TT

Intravenous Immunoglobulin-Induced Pulmonary Embolism: It Is Time to Act!

American journal of therapeutics. 2016;23(4):e1074-7

Gómez Pérez M, Hernández Segurado M, Bonilla Porras M, Bécares Martínez J

Severe thromboembolic complications associated with the administration of intravenous immunoglobulins.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2012;36(3):166-7

Rajabally YA, Kearney DA

Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study.

Journal of the neurological sciences. 2011;308(1-2):124-7

Milani C, Dalia SM, Colvin GA

Thromboembolic complications of intravenous immunoglobulin (IVIG) in an immunocompromised patient with Chronic Lymphocytic Leukemia: a case report.

Cases journal. 2009;2:9078

Sheehan DJ, Lesher JL Jr

Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris.

Cutis. 2004;73(6):403-6

Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D

Pulmonary embolism after intravenous immunoglobulin.

Journal of the Royal Society of Medicine. 2001;94(4):187-8